Ifenprodil API Manufacturers
compare suppliers & get competitive offers
Filters
Reset
Selected filters:
Type
Production region
Qualifications
Country of origin
Producer
+ 0
All certificates
Replies slower than most
Producer
+ 0
All certificates
Replies slower than most
How does it work?
You can register for free as long as you are registering on behalf of a legal company related to the pharmaceutical industry
Search in the search bar the product that you’re looking for. We’ll show you an overview of all available suppliers. Use the filters to select the relevant suppliers only
Have you found interesting suppliers? Then it’s time to contact them. Use the send inquiry button and send them a message. You can send for each product, 3 inquiries per week
Suppliers get notified by Pharmaoffer that they’ve received a new inquiry. They will come back to you with their questions, certificates, and offer in the chat on Pharmaoffer. We will send you an email in case of any news
Does the supplier meet your quality and commercial requirements? Then you can place the order. Just follow the steps of our order module
Looking for Ifenprodil API 23210-56-2?
- Description:
- Here you will find a list of producers, manufacturers and traders of Ifenprodil. You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Ifenprodil
- Synonyms:
- Cas Number:
- 23210-56-2
- DrugBank number:
- DB08954
- Unique Ingredient Identifier:
- R8OE3P6O5S
About Ifenprodil
It's time for some technical information for the ones who understand chemistry: N-methyl-D-aspartate (NMDA) receptors (NMDARs) are members of the ionotropic glutamate receptor family, with key roles in brain development and neurological function NMDARs are heterotetramers that typically involve a dimer of dimers of both GluN1 and GluN2A-D subunits, with each subunit itself composed of an N-terminal domain (NTD), a ligand-binding domain (LBD), a transmembrane domain, and a C-terminal cytoplasmic domain. Binding at the LBD of the agonists glycine (or D-serine) to the GluN1 subunits and of glutamate to the GluN2 subunits is a regulatory mechanism for channel activation. In addition, allosteric modulators are known to bind at the NTDs and form another layer of regulation One such allosteric regulator is ifenprodil, which was first shown to bind the NMDARs in the 1990s, and specifically to those NMDARs containing the GluN2B subunit. Further studies elucidated that ifenprodil binds strongly at the inter-subunit interface of adjacent GluN1 and GluN2B NTDs, where it acts as a non-competitive antagonist Although ifenprodil has received considerable interest in its potential neuromodulatory activities in psychiatric conditions.
More information such as the structure, indication or toxicity is available on Drugbank, click the ID above.
Ifenprodil is a type of NMDA antagonists
NMDA antagonists, a subcategory of pharmaceutical active pharmaceutical ingredients (APIs), play a crucial role in the field of pharmacology and neuroscience. NMDA (N-Methyl-D-Aspartate) receptors are a specific type of glutamate receptor found in the central nervous system (CNS) and are involved in various neurological processes, including learning, memory, and pain perception.
NMDA antagonists are compounds that inhibit the activity of NMDA receptors by binding to their recognition sites. This action blocks the influx of calcium ions into neurons, which regulates the excitation and transmission of nerve impulses. By modulating NMDA receptor activity, these antagonists can influence synaptic plasticity and neuronal signaling, making them potential candidates for treating conditions such as Alzheimer's disease, neuropathic pain, and psychiatric disorders.
Pharmaceutical API manufacturers produce NMDA antagonists using advanced chemical synthesis techniques. These APIs undergo rigorous quality control tests to ensure purity, potency, and safety. The manufacturing process involves precise measurements and strict adherence to regulatory guidelines to achieve consistent product quality.
Research and development efforts in the field of NMDA antagonists aim to enhance their therapeutic potential and minimize potential side effects. Ongoing studies explore the optimization of dosage forms, drug delivery systems, and novel chemical structures. This research strives to improve the pharmacokinetic properties, bioavailability, and target selectivity of NMDA antagonists, thereby maximizing their efficacy and minimizing adverse reactions.
Overall, NMDA antagonists are a promising class of pharmaceutical APIs that hold significant potential for the development of novel therapies for neurological disorders. Continued advancements in this field will contribute to improving patient outcomes and enhancing our understanding of the complex mechanisms underlying brain function.
Ifenprodil (NMDA antagonists), classified under Central Nervous System Agents
Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.
CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.
The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.
Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.
Ifenprodil manufacturers | traders | suppliers
We have 2 companies offering Ifenprodil produced in 1 different countries.
Get in contact with the supplier of your choice:
- Osaka Synthetic Chemical Lab from Japan, product country of origin Japan
- Iwaki Seiyaku from Japan, product country of origin Japan
Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.
You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.
